OMEROS CORP Sales Revenue, Goods, Net (Deprecated 2018-01-31)
OMEROS CORP (OMER) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $1.66 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-08-09
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $1.66M, a 90.35% decline year-over-year.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.59M, a 87.04% decline year-over-year.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $13.76M, a 6.62% increase year-over-year.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $21.66M, a 91.85% increase year-over-year.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $64.83M, a 56.42% increase from fiscal 2016.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $41.44M, a 212.45% increase from fiscal 2015.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $13.26M.
- OMEROS CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $0.00.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $1.66M 10-Q · filed 2018-08-09 | $3.24M 10-Q · filed 2018-08-09 | $17.00M derived: sum of 3 quarters · filed 2018-08-09 | $38.66M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | $1.59M 10-Q · filed 2018-05-10 | $15.35M derived: sum of 2 quarters · filed 2018-05-10 | $37.01M derived: sum of 3 quarters · filed 2018-05-10 | $54.16M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-12-31 | $13.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $35.42M derived: sum of 2 quarters · filed 2018-03-01 | $52.57M derived: sum of 3 quarters · filed 2018-08-09 | $64.83M 10-K · filed 2018-03-01 |
| 2017-09-30 | $21.66M 10-Q · filed 2017-11-09 | $38.81M derived: sum of 2 quarters · filed 2018-08-09 | $51.07M 10-Q · filed 2017-11-09 | $63.97M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-06-30 | $17.15M 10-Q · filed 2018-08-09 | $29.41M 10-Q · filed 2018-08-09 | $42.31M derived: sum of 3 quarters · filed 2018-08-09 | $53.60M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $12.26M 10-Q · filed 2018-05-10 | $25.16M derived: sum of 2 quarters · filed 2018-05-10 | $36.45M derived: sum of 3 quarters · filed 2018-05-10 | $46.45M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $24.19M derived: sum of 2 quarters · filed 2018-03-01 | $34.20M derived: sum of 3 quarters · filed 2018-03-01 | $41.44M 10-K · filed 2018-03-01 |
| 2016-09-30 | $11.29M 10-Q · filed 2017-11-09 | $21.29M derived: sum of 2 quarters · filed 2017-11-09 | $28.54M 10-Q · filed 2017-11-09 | $35.20M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $10.00M 10-Q · filed 2017-08-08 | $17.25M 10-Q · filed 2017-08-08 | $23.91M derived: sum of 3 quarters · filed 2018-03-01 | $27.15M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $7.25M 10-Q · filed 2017-05-10 | $13.90M derived: sum of 2 quarters · filed 2018-03-01 | $17.15M derived: sum of 3 quarters · filed 2018-03-01 | $20.27M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $9.90M derived: sum of 2 quarters · filed 2018-03-01 | $13.03M derived: sum of 3 quarters · filed 2018-03-01 | $13.26M 10-K · filed 2018-03-01 |
| 2015-09-30 | $3.24M 10-Q · filed 2016-11-09 | $6.37M derived: sum of 2 quarters · filed 2016-11-09 | $6.61M 10-Q · filed 2016-11-09 | $6.61M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $3.13M 10-Q · filed 2016-08-09 | $3.36M 10-Q · filed 2016-08-09 | $3.36M derived: sum of 3 quarters · filed 2017-03-16 | $3.36M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $238.00K 10-Q · filed 2016-05-10 | $238.00K derived: sum of 2 quarters · filed 2017-03-16 | $238.00K derived: sum of 3 quarters · filed 2017-03-16 | $238.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $0.00 derived: sum of 3 quarters · filed 2017-03-16 | $0.00 10-K · filed 2017-03-16 |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |